Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting ...

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating ...

Will Pih, co-founder, Two Labs, explains how specialty pharmacies and manufacturers are adapting to financial pressures in rare disease care through patient-centric services, hub innovation, and ...

Market access is about aligning internal strategies with external realities that often change without warning and at a ...

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar ...

The afternoon of day 2 at Asembia’s AXS25 Summit offered various intriguing sessions to pick from, including one on ...

The famous trees, and the festival associated with their blossoming each spring, is part of a tradition for the global ...

Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase ...

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on ...

The emerging biotech scene in Chicago has the potential to develop new treatments and technologies, but funding cuts from the ...

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping ...

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.